Bessemer Group
SYRS

Bessemer Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bessemer Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,490
Closed -$585K – 1710
2020
Q2 		$585K Buy
+5,490
New +$493K ﹤0.01% 927

Other funds holding SYRS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bessemer Group's SYRS Position: Q3 2020 in Review

Bessemer Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2020, closing a stake of 5,490 shares — an estimated $585K sold.

Bessemer Group first reported a position in SYRS in Q2 2020 and held it in 1 quarter. The position peaked at $585K in Q2 2020. 93 funds tracked by Wall St. Rank hold SYRS as of Q3 2020.

  • Bessemer Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 5,490 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $585K.
  • Bessemer Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $585K in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.